Welcome to our dedicated page for Ayala Pharm news (Ticker: ADXS), a resource for investors and traders seeking the latest updates and insights on Ayala Pharm stock.
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS) is a publicly traded, clinical-stage oncology company that focuses on the development and commercialization of small molecule therapeutics. The company primarily targets rare tumors and aggressive cancers through its innovative treatments. Ayala's leading candidate, AL102, is an investigational small molecule gamma secretase inhibitor currently in the Phase 3 RINGSIDE study for the treatment of desmoid tumors. The promising data from Phase 2 shows significant anti-tumor activity and high overall response rates.
Ayala's strategic vision was further enhanced by its merger with Biosight Ltd., which brought aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML), into its portfolio. AL102 has received FDA Fast Track and Orphan Drug Designations for the treatment of desmoid tumors, highlighting its potential impact in oncology.
Recently, Ayala entered into a definitive asset purchase agreement with Immunome, Inc. to sell AL102 and related drug candidate AL101. This agreement, valued at over $50 million, will allow Immunome to advance AL102 through clinical trials and towards potential commercialization. The transaction is expected to be completed by the end of Q3 2024, pending regulatory approvals.
Ayala is committed to advancing its remaining pipeline, which includes aspacytarabine (BST-236) for AML. Despite the sale of its key assets, Ayala continues to focus on developing impactful treatments within oncology, leveraging its expertise and the clinical data it has gathered.
For more information, please visit www.ayalapharma.com.
Advaxis, Inc. (OTCQX: ADXS) reported its fiscal year 2021 results, showcasing a focus on immunotherapy development. Key highlights include updated clinical data from the Phase 1/2 trial of ADXS-503 in NSCLC, revealing a 15% overall response rate and a 67% disease control rate in newly diagnosed subjects. The company initiated a Phase 1 trial for ADXS-504 targeting early prostate cancer. Financially, Advaxis ended the year with $41.6 million in cash, reporting a net loss of $17.9 million, down from $26.5 million in FY 2020.
Advaxis, Inc. (OTCQX: ADXS) announced a private placement agreement for 1,000,000 shares of Series D convertible redeemable preferred stock, totaling $5,000,000. Each share is priced at $4.75 with a 5% discount. The shares are convertible into common stock at $0.25 per share, contingent on stockholder approval for a reverse stock split. The offering is expected to close on January 31, 2022. This move aims to strengthen the company's financial position amid ongoing clinical development of its immunotherapy products.
Advaxis, Inc. (Nasdaq: ADXS) reports updated Phase 1/2 study results for ADXS-503 combined with KEYTRUDA in non-small cell lung cancer (NSCLC) patients. In Part B, the overall response rate (ORR) reached 15.4% and disease control rate (DCR) at 46% among 13 evaluable patients. Notably, two patients had partial responses lasting 702 and 189 days. Part C shows promising data with a 67% DCR in three newly diagnosed patients. The treatment exhibited tolerability with mild side effects, and further enrollment is ongoing to deepen understanding of the drug's potential benefits.
Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company, announces its successful transition to the OTCQX Best Market, effective December 23, 2021. This market is for established companies that meet high financial and corporate governance standards. The move comes after being listed on Nasdaq. Advaxis specializes in developing innovative immunotherapy products utilizing Listeria monocytogenes to enhance anti-tumor T cell immunity. This transition is expected to provide greater visibility and accessibility for the company and its shareholders.
Advaxis, Inc. (Nasdaq: ADXS) announced the outcome of its recent stockholder meetings held on December 7 and 16, 2021. Stockholders approved Proposal 1, allowing the merger with Biosight to proceed. However, Proposal 2, which involved a reverse stock split, did not receive sufficient votes for approval. This reverse stock split was necessary for completing the merger. Advaxis plans to explore additional options to maximize stockholder value and will provide further updates soon.
Advaxis, Inc. (Nasdaq: ADXS) announced that stockholders approved the merger with Biosight, signaling support for Proposal 1 and Proposal 4 concerning executive compensation. A special meeting was held on December 7, 2021, with a majority favoring the merger. However, Proposal 2, the reverse stock split, requires a higher threshold for approval, necessitating stockholder support by December 16, 2021. Without it, the merger's completion is at risk. Independent proxy advisory firms ISS and Glass Lewis have recommended approval of all proposals.
Advaxis, Inc. (Nasdaq: ADXS) emphasizes the importance of stockholders voting in favor of all proposals for its merger with Biosight, aimed at enhancing long-term value. The company believes the merger will strengthen its capital position and facilitate the advancement of a diverse portfolio focused on liquid and solid tumors. The special meeting for stockholder approval was initially held on November 16, 2021, and adjourned to December 7, 2021. Leading proxy advisory firms ISS and Glass Lewis have recommended voting 'FOR' all proposals.
Advaxis, Inc. (ADXS) announced the extension from the Nasdaq Hearings Panel until December 20, 2021, to finalize its merger with Biosight, Ltd. This follows a prior extension granted due to non-compliance with the $1.00 bid price requirement. The merger aims to reinforce Advaxis's position in the biotechnology sector focused on innovative therapeutics for hematological malignancies. The special stockholder meeting for merger approval has been adjourned to December 7, 2021, allowing stockholders to participate online. The company is optimistic about meeting all Nasdaq listing requirements by the new deadline.
Advaxis, Inc. (Nasdaq: ADXS) is urging stockholders to vote for the proposed merger with Biosight, highlighting potential benefits from the transaction. The merger, adjourned to December 7, 2021, is supported by key institutional investors who have committed $21 million in financing contingent upon stockholder approval. If the merger is approved, Advaxis anticipates a stronger, more diversified pipeline, improved liquidity, and enhanced capital-raising opportunities. Conversely, a failure to approve could leave Advaxis in a materially weaker position, facing imminent delisting and reduced capital stability.
Advaxis, Inc. (Nasdaq: ADXS) announced a video message emphasizing the strategic importance of its proposed merger with Biosight Ltd. The transaction aims to enhance the capital position of the combined company, facilitating the advancement of drug candidates for various tumors. Stockholder approval is crucial, with a special meeting scheduled for November 16, 2021. An independent advisory firm, ISS, supports the merger, noting a thorough review process. Stockholders are encouraged to vote in favor of all proposals to promote long-term value.
FAQ
What is the current stock price of Ayala Pharm (ADXS)?
What is the market cap of Ayala Pharm (ADXS)?
What is the primary focus of Ayala Pharmaceuticals?
What are Ayala’s leading candidates under development?
What significant recent transaction has Ayala Pharmaceuticals entered into?
What is AL102 and what phase is it currently in?
What are the FDA designations achieved by AL102?
What was the result of Ayala's merger with Biosight Ltd.?
What is aspacytarabine (BST-236) used for?
What recent clinical milestone has Ayala achieved?
What is the significance of the sale of AL102 to Immunome?
What will Ayala focus on after the sale of AL102?
